# A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

> **NCT06673238** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 96 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ABBV-722
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06673238
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-29
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06673238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06673238, "A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06673238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*